Macquarie Group
KROS icon

Macquarie Group’s Keros Therapeutics KROS Stock Holding History

Macquarie Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,372
Closed -$61K – 2083
2022
Q3 		$61K Sell
1,372
-250
-15% -$8.66K ﹤0.01% 1899
2022
Q2 		$45K Hold
1,622
– – ﹤0.01% 2077
2022
Q1 		$88 Hold
1,622
– – ﹤0.01% 1988
2021
Q4 		$95K Hold
1,622
– – ﹤0.01% 1954
2021
Q3 		$64K Buy
1,622
+1,372
+549% +$48.8K ﹤0.01% 2139
2021
Q2 		$11K Hold
250
– – ﹤0.01% 2461
2021
Q1 		$15K Buy
+250
New +$15.8K ﹤0.01% 2336

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $22.1B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return